Myostatin serum levels in heart failure

Zamora, Elisabet; Lupón, Josep; Simó, Rafael; Galán, Amparo

doi:10.1093/eurjhf/hfq190

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicates that the myostatin system does not appear to be responsible for cardiac muscle wasting. Similar observations have been made in patients with chronic heart failure (43).…”

Section: Resultssupporting

confidence: 83%

Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats

et al. 2011

View full text Add to dashboard Cite

Abstract. Cachexia is a common systemic manifestation. Additionally, myostatin is known to be a negative regulator of skeletal muscle development. The present study aimed to investigate whether formoterol down-regulates the myostatin system in skeletal muscle of tumour-bearing rats. Real-time PCR and Western blotting were used for the analysis. Results showed that rats bearing the Yoshida AH-130 ascites hepatoma, a cachexia-inducing tumour, exhibited marked muscle wasting that affected the mass of the muscles studied. The cachectic animals exhibited a significant increase in the mRNA levels of the myostatin receptor (ActIIB) in gastrocnemius muscles. Notably, the expression of the various forms of follistatin, a protein with the opposite effects to those of myostatin, was significantly reduced as a result of the implantation of the tumour. When the animals were treated with formoterol, a β-agonist with anti-cachectic potential, increases in skeletal muscle weights were observed. The β-agonist significantly increased levels of various follistatin isoforms and significantly decreased the expression levels of the myostatin receptor. In addition, formoterol treatment resulted in a significant decrease of the myostatin protein content of the gastrocnemius muscle. In conclusion, the results presented indicate that certain anabolic actions of formoterol on the skeletal muscle of cachectic animals may be mediated via the myostatin system.

show abstract

“…This indicates that the myostatin system does not appear to be responsible for cardiac muscle wasting. Similar observations have been made in patients with chronic heart failure (43).…”

Section: Resultssupporting

confidence: 83%

Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats

et al. 2011

View full text Add to dashboard Cite

show abstract

Neutrophil-lymphocyte ratio: A prognostic tool in patients with in-hospital cardiac arrest

Patel

Vendittelli

Garg

et al. 2019

WJCCM

View full text Add to dashboard Cite

BACKGROUND In-hospital cardiac arrest (IHCA) portends a poor prognosis and survival to discharge rate. Prognostic markers such as interleukin-6, S-100 protein and high sensitivity C reactive protein have been studied as predictors of adverse outcomes after return of spontaneous circulation (ROSC); however; these variables are not routine laboratory tests and incur additional cost making them difficult to incorporate and less attractive in assessing patient’s prognosis. The neutrophil-lymphocyte ratio (NLR) is a marker of adverse prognosis for many cardiovascular conditions and certain types of cancers and sepsis. We hypothesize that an elevated NLR is associated with poor outcomes including mortality at discharge in patients with IHCA. AIM To determine the prognostic significance of NLR in patients suffering IHCA who achieve ROSC. METHODS A retrospective study was performed on all patients who had IHCA with the advanced cardiac life support protocol administered in a large urban community United States hospital over a one-year period. Patients were divided into two groups based on their NLR value (NLR < 4.5 or NLR ≥ 4.5). This cutpoint was derived from receiving operator characteristic curve analysis (area under the curve = 0.66) and provided 73% positive predictive value, 82% sensitivity and 42% specificity for predicting in-hospital death after IHCA. The primary outcome was death or discharge at 30 d, whichever came first. RESULTS We reviewed 153 patients with a mean age of 66.1 ± 16.3 years; 48% were female. In-hospital mortality occurred in 65%. The median NLR in survivors was 4.9 (range 0.6-46.5) compared with 8.9 (0.28-96) in non-survivors ( P = 0.001). A multivariable logistic regression model demonstrated that an NLR above 4.55 [odds ratio (OR) = 5.20, confidence interval (CI): 1.5-18.3, P = 0.01], older age (OR = 1.03, CI: 1.00-1.07, P = 0.05), and elevated serum lactate level (OR = 1.20, CI: 1.03-1.40, P = 0.02) were independent predictors of death. CONCLUSION An NLR ≥ 4.5 may be a useful marker of increased risk of death in patients with IHCA.

show abstract

Myostatin serum levels in heart failure

Cited by 2 publications

References 3 publications

Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats

Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats

Neutrophil-lymphocyte ratio: A prognostic tool in patients with in-hospital cardiac arrest

Contact Info

Product

Resources

About